New Alzheimer ' s drug shows some promise, but has big price tag

The Food and Drug Administration recently granted fast-track approval to a new Alzheimer’s drug designed to slow the rate of cognitive decline for individuals in the early stages of the disease. Lecanemab, which will be sold under the brand name Leqembi, was developed jointly by Eisai 4523, and…#lecanemab #leqembi #eisai4523 #biogenbiib #medicare #fda #lilly #aduhelm #medicaid #eisai
Source: Reuters: Health - Category: Consumer Health News Source Type: news